- Home
- HHS vs CYTH Comparison
HHS vs CYTH Comparison
Compare HHS & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- CYTH
- Stock Information
- Founded
- HHS 1923
- CYTH 1990
- Country
- HHS United States
- CYTH United States
- Employees
- HHS N/A
- CYTH N/A
- Industry
- HHS Advertising
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- CYTH Health Care
- Exchange
- HHS Nasdaq
- CYTH Nasdaq
- Market Cap
- HHS 39.4M
- CYTH 31.9M
- IPO Year
- HHS N/A
- CYTH N/A
- Fundamental
- Price
- HHS $5.05
- CYTH $0.91
- Analyst Decision
- HHS
- CYTH Buy
- Analyst Count
- HHS 0
- CYTH 3
- Target Price
- HHS N/A
- CYTH $0.95
- AVG Volume (30 Days)
- HHS 17.7K
- CYTH 4.5M
- Earning Date
- HHS 03-13-2025
- CYTH 03-17-2025
- Dividend Yield
- HHS N/A
- CYTH N/A
- EPS Growth
- HHS N/A
- CYTH N/A
- EPS
- HHS N/A
- CYTH N/A
- Revenue
- HHS $187,604,000.00
- CYTH $870,725.00
- Revenue This Year
- HHS N/A
- CYTH N/A
- Revenue Next Year
- HHS $4.05
- CYTH $24.49
- P/E Ratio
- HHS N/A
- CYTH N/A
- Revenue Growth
- HHS N/A
- CYTH N/A
- 52 Week Low
- HHS $4.85
- CYTH $0.55
- 52 Week High
- HHS $8.87
- CYTH $1.79
- Technical
- Relative Strength Index (RSI)
- HHS 38.02
- CYTH 53.59
- Support Level
- HHS $5.31
- CYTH $0.85
- Resistance Level
- HHS $5.33
- CYTH $1.45
- Average True Range (ATR)
- HHS 0.19
- CYTH 0.13
- MACD
- HHS -0.02
- CYTH -0.00
- Stochastic Oscillator
- HHS 9.26
- CYTH 22.83
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.